Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant chemotherapy for soft tissue sarcoma.

Paolo G Casali1, Piero Picci

  • 1Adult Sarcoma Medical Oncology Unit, Istituto Nazionale Tumori, Milano, Italy. paolo.casali@istitutotumori.mi.it

Current Opinion in Oncology
|June 4, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Training European Health Care Providers in Adolescent and Young Adult (AYA) Oncology: The Joint Action Networks of Expertise (JANE) on AYA with Cancer Perspective.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study.

The Lancet. Oncology·2026
Same author

Training European Health Care Providers in Adolescent and Young Adult (AYA) Oncology: The Joint Action Networks of Expertise (JANE) on AYA with Cancer Perspective.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

ASO Visual Abstract: Refining the Contemporary Management of Primary Retroperitoneal Soft Tissue Sarcoma: Outcome Improvement Over Time at a Single Institution.

Annals of surgical oncology·2026
Same author

[Expression of Concern] Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation.

Oncology reports·2026
Same author

Potential biomarkers of Ewing sarcoma identified through a Europe-wide analysis of prospectively collected samples.

Scientific reports·2026

Adjuvant chemotherapy may offer limited benefits for adult soft tissue sarcomas, particularly for high-risk patients. Evidence suggests a potential delay in relapse, but long-term survival benefits remain difficult to definitively prove.

Area of Science:

  • Oncology
  • Medical Oncology
  • Sarcoma Research

Background:

  • Soft tissue sarcomas are rare malignancies.
  • Adjuvant therapy aims to eliminate micrometastatic disease post-surgery.
  • Current evidence for adjuvant chemotherapy in soft tissue sarcomas is largely based on trials from the 1970s onwards.

Purpose of the Study:

  • To review the current knowledge on adjuvant medical therapy for adult soft tissue sarcomas.
  • To synthesize findings from existing clinical trials and recent evidence.

Main Methods:

  • Review of controlled clinical trials and nonrandomized evidence.
  • Analysis of retrospective studies and meta-analyses.
  • Evaluation of chemotherapy regimens, including Doxorubicin and anthracycline plus Ifosfamide.

Related Experiment Videos

Main Results:

  • Conflicting results exist regarding the benefit of adjuvant chemotherapy.
  • A delay in relapse is suggested for some patients, but permanent benefit is uncertain.
  • Doxorubicin-based regimens show a slight benefit; anthracycline plus Ifosfamide may offer more, but with less evidence.

Conclusions:

  • Adjuvant chemotherapy might provide some benefit in soft tissue sarcoma, likely limited and for high-risk patients.
  • Fully active chemotherapy regimens are necessary for potential efficacy.
  • Findings are most established for extremity soft tissue sarcomas but may extend to other sites.